Applications of Advanced Natural Language Processing for Clinical Pharmacology.

Journal: Clinical pharmacology and therapeutics
PMID:

Abstract

Natural language processing (NLP) is a branch of artificial intelligence, which combines computational linguistics, machine learning, and deep learning models to process human language. Although there is a surge in NLP usage across various industries in recent years, NLP has not been widely evaluated and utilized to support drug development. To demonstrate how advanced NLP can expedite the extraction and analyses of information to help address clinical pharmacology questions, inform clinical trial designs, and support drug development, three use cases are described in this article: (1) dose optimization strategy in oncology, (2) common covariates on pharmacokinetic (PK) parameters in oncology, and (3) physiologically-based PK (PBPK) analyses for regulatory review and product label. The NLP workflow includes (1) preparation of source files, (2) NLP model building, and (3) automation of data extraction. The Clinical Pharmacology and Biopharmaceutics Summary Basis of Approval (SBA) documents, US package inserts (USPI), and approval letters from the US Food and Drug Administration (FDA) were used as our source data. As demonstrated in the three example use cases, advanced NLP can expedite the extraction and analyses of large amounts of information from regulatory review documents to help address important clinical pharmacology questions. Although this has not been adopted widely, integrating advanced NLP into the clinical pharmacology workflow can increase efficiency in extracting impactful information to advance drug development.

Authors

  • Joy C Hsu
    Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Michael Wu
    Department of Electrical Engineering, University of California Los Angeles (UCLA), USA. ozcan@ucla.edu.
  • Chloe Kim
    Computational Sciences, Genentech, Inc., South San Francisco, California, USA.
  • Bianca Vora
    Department of Bioengineering and Therapeutic Sciences, UCSF, San Francisco, California, United States of America.
  • Yi Ting Kayla Lien
    Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Ashutosh Jindal
    Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Kenta Yoshida
    Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, Japan.
  • Sonoko Kawakatsu
    Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Jeremy Gore
    Capgemini America, Inc., New York, New York, USA.
  • Jin Y Jin
    Department of Clinical Pharmacology, Roche/Genentech, South San Francisco, California, USA.
  • Christina Lu
    Computational Sciences, Genentech, Inc., South San Francisco, California, USA.
  • Bingyuan Chen
    Computational Sciences, Genentech, Inc., South San Francisco, California, USA.
  • Benjamin Wu
    Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York 11794, United States.